Post-Conference Perspectives: Urothelial Carcinoma 2022 Year in Review - Episode 2

Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma

,

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

EP. 1: Incidence and Risk Factors for Urothelial Carcinoma
Now Viewing
EP. 2: Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
EP. 3: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
EP. 4: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study
EP. 5: Treatment Options for Frontline Metastatic Urothelial Carcinoma
EP. 6: Outcomes of the JAVELIN Bladder 100 Trial
EP. 7: Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab
EP. 8: Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022

Related Content:

Post-Conference Perspectives: Urothelial Carcinoma 2022 Year in ReviewUrothelial CancerOncLive News Network®
Single-Agent Immune Therapy in UC: The Need for More
Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
Dr Sharma on the Impact of Frontline Treatment Advances in Advanced Bladder Cancer